Halometasone

Halometasone is a corticosteroid compound that can reduce the expression of serum leukotriene B4 (LTB4) and thymic stromal lymphopoietin (TSLP) . Halometasone can be used in research on psoriasis and eczematous skin diseases[1].

Product Specifications

CAS Number

[50629-82-8]

UNSPSC

12352211

Hazard Statement

H302, H312, H332, H351

Target

Leukotriene Receptor

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Purity

98.47

Smiles

F[C@@]12[C@](C[C@@H](C([C@@]2(C=C3Cl)C)=CC3=O)F)([H])[C@@]4([H])[C@](C[C@@H]1O)([C@](O)([C@@H](C4)C)C(CO)=O)C

Molecular Formula

C22H27ClF2O5

Molecular Weight

444.90

Precautions

H302, H312, H332, H351

References & Citations

[1]Zhu J W, et al. Role of VEGF receptors in normal and psoriatic human keratinocytes: evidence from irradiation with different UV sources[J]. PLoS One, 2013, 8 (1) : e55463.|[2]Cao J, et al. Effect of halometasone cream combined with Simiao pill on the therapeutic effect and expression of serum leukotriene B4 (LTB4) and thymic stromal lymphopoietin (TSLP) in patients with eczema, and the factors influencing its clinical efficacy. Ann Palliat Med. 2021 Nov;10 (11) :11643-11652.